Terminated PHASE2 INTERVENTIONAL 2-arm NCT05983367

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer

Sponsor: Inspirna, Inc.

Conditions Colorectal Cancer Metastatic Colon Cancer

Interventions Bevacizumab FOLFIRI regimen Ompenaclid Placebo

Updated 13 times since 2023 Last updated: Feb 2, 2026 Started: Oct 10, 2023 Primary completion: Jan 31, 2025 Completion: Mar 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

At the time of the primary analysis, results did not meet the primary endpoint

Other Colorectal Cancer trials with similar outcome

Browse all Colorectal Cancer trials

Listed as NCT05983367, this PHASE2 trial focuses on Colorectal Cancer and Metastatic Colon Cancer and remains terminated or withdrawn. Sponsored by Inspirna, Inc., it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Apr 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Dec 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE2

▶ Show 8 earlier versions

Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — May 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inspirna, Inc.

Data source: Inspirna, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderlecht, Belgium , Antwerp, Belgium , Barcelona, Spain , Besançon, France , Bonheiden, Belgium , Brussels, Belgium , Charleroi, Belgium , Córdoba, Spain , Dijon, France , Leuven, Belgium and 13 more locations